Details
| Stereochemistry | MIXED |
| Molecular Formula | C10H12N4O5.3C9H9NO3.3C5H13NO |
| Molecular Weight | 1115.2325 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 7 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(O)CN(C)C.CC(O)CN(C)C.CC(O)CN(C)C.CC(=O)NC1=CC=C(C=C1)C(O)=O.CC(=O)NC2=CC=C(C=C2)C(O)=O.CC(=O)NC3=CC=C(C=C3)C(O)=O.OC[C@H]4O[C@H]([C@H](O)[C@@H]4O)N5C=NC6=C5N=CNC6=O
InChI
InChIKey=YLDCUKJMEKGGFI-QCSRICIXSA-N
InChI=1S/C10H12N4O5.3C9H9NO3.3C5H13NO/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18;3*1-6(11)10-8-4-2-7(3-5-8)9(12)13;3*1-5(7)4-6(2)3/h2-4,6-7,10,15-17H,1H2,(H,11,12,18);3*2-5H,1H3,(H,10,11)(H,12,13);3*5,7H,4H2,1-3H3/t4-,6-,7-,10-;;;;;;/m1....../s1
| Molecular Formula | C10H12N4O5 |
| Molecular Weight | 268.2261 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | C9H9NO3 |
| Molecular Weight | 179.1727 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C5H13NO |
| Molecular Weight | 103.1628 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
DescriptionSources: https://www.medicines.org.uk/emc/medicine/27089Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/2431857
Sources: https://www.medicines.org.uk/emc/medicine/27089
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/2431857
Inosine pranobex is an antiviral drug that is a combination of inosine and dimepranol acedoben (a salt of acetamidobenzoic acid and dimethylaminoisopropanol) in a ratio of 1 to 3. Inosine pranobex is used to treat mucocutaneous infections due to herpes simplex virus (type 1 and/or type II), genital warts as adjunctive therapy to podophyllin or carbon dioxide laser, and subacute sclerosing panencephalitis. The in vivo antiviral and activity of inosine pranobex is believed to result from an enhancement of host immune responses due to the drug. The drug does not by itself stimulate resting lymphocytes, but augments immunological processes by lymphocytes once they have been triggered by mitogens or viral antigens.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0006955 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2431857 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | IMUNOVIR Approved UseImunovir tablets are indicated in the management of mucocutaneous infections due to herpes simplex virus (type 1 and/or type II), genital warts as adjunctive therapy to podophyllin or carbon dioxide laser, and subacute sclerosing panencephalitis. Launch Date1983 |
|||
| Primary | IMUNOVIR Approved UseImunovir tablets are indicated in the management of mucocutaneous infections due to herpes simplex virus (type 1 and/or type II), genital warts as adjunctive therapy to podophyllin or carbon dioxide laser, and subacute sclerosing panencephalitis. Launch Date1983 |
|||
| Primary | IMUNOVIR Approved UseImunovir tablets are indicated in the management of mucocutaneous infections due to herpes simplex virus (type 1 and/or type II), genital warts as adjunctive therapy to podophyllin or carbon dioxide laser, and subacute sclerosing panencephalitis. Launch Date1983 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effect of isoprinosine on rotavirus replication in vitro. | 1996-02 |
|
| Inhibition of Pneumocystis carinii dihydropteroate synthetase by para-acetamidobenzoic acid: possible mechanism of action of isoprinosine in human immunodeficiency virus infection. | 1993-06 |
|
| Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs. | 1992-09 |
|
| Activities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumonia. | 1992-09 |
|
| No effect of isoprinosine on HIV infection in vitro. | 1990-10 |
|
| Inhibitory effect of selected antiviral compounds on measles (SSPE) virus replication in vitro. | 1989-09 |
|
| Influence of methisoprinol (isoprinosine) on HIV-infected human lymphocytes: in vitro immunological, virological, and ultrastructural studies. | 1989 |
|
| Isoprinosine-induced modulation of T-helper-cell subsets and antigen-presenting monocytes (Leu M3 + Ia +) resulted in improvement of T- and B-lymphocyte functions, in vitro in ARC and AIDS patients. | 1987-11 |
|
| In-vitro inhibition of LAV/HTLV-III infected lymphocytes by dithiocarb and inosine pranobex. | 1985-12-21 |
|
| Effect of isoprinosine against influenza and some other viruses causing respiratory diseases. | 1972-09 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.medicines.org.uk/emc/medicine/27089
Mucocutaneous herpes simplex: 1 g q.d.s. (4g daily), for 7 -14 days. Genital warts: 1g t.d.s. (3g daily), for 14-28 days as adjunctive therapy to podophyllin or carbon dioxide laser. Subacute sclerosing panencephalitis (SSPE): 50-100mg/kg daily, in divided does every 4 hours.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2431857
Inosine pranobex has been shown to stimulate various indices of metabolic activity of macrophages and monocytes. In vitro exposure to inosine pranobex or to 24-hour supernatants obtained from mononuclear cells pretreated with the drug restored chemotaxis to normal or near normal levels. Incubation with inosine pranobex in vitro stimulated the production of interleukin-l (lymphocyte activating factor) in human monocytes.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:55:35 GMT 2025
by
admin
on
Mon Mar 31 17:55:35 GMT 2025
|
| Record UNII |
W1SO0V223F
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QJ05AX05
Created by
admin on Mon Mar 31 17:55:35 GMT 2025 , Edited by admin on Mon Mar 31 17:55:35 GMT 2025
|
||
|
NCI_THESAURUS |
C2139
Created by
admin on Mon Mar 31 17:55:35 GMT 2025 , Edited by admin on Mon Mar 31 17:55:35 GMT 2025
|
||
|
FDA ORPHAN DRUG |
26888
Created by
admin on Mon Mar 31 17:55:35 GMT 2025 , Edited by admin on Mon Mar 31 17:55:35 GMT 2025
|
||
|
WHO-ATC |
J05AX05
Created by
admin on Mon Mar 31 17:55:35 GMT 2025 , Edited by admin on Mon Mar 31 17:55:35 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
6048
Created by
admin on Mon Mar 31 17:55:35 GMT 2025 , Edited by admin on Mon Mar 31 17:55:35 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB14214MIG
Created by
admin on Mon Mar 31 17:55:35 GMT 2025 , Edited by admin on Mon Mar 31 17:55:35 GMT 2025
|
PRIMARY | |||
|
D007542
Created by
admin on Mon Mar 31 17:55:35 GMT 2025 , Edited by admin on Mon Mar 31 17:55:35 GMT 2025
|
PRIMARY | |||
|
100000092431
Created by
admin on Mon Mar 31 17:55:35 GMT 2025 , Edited by admin on Mon Mar 31 17:55:35 GMT 2025
|
PRIMARY | |||
|
DB13156
Created by
admin on Mon Mar 31 17:55:35 GMT 2025 , Edited by admin on Mon Mar 31 17:55:35 GMT 2025
|
PRIMARY | |||
|
135449284
Created by
admin on Mon Mar 31 17:55:35 GMT 2025 , Edited by admin on Mon Mar 31 17:55:35 GMT 2025
|
PRIMARY | |||
|
4576
Created by
admin on Mon Mar 31 17:55:35 GMT 2025 , Edited by admin on Mon Mar 31 17:55:35 GMT 2025
|
PRIMARY | |||
|
36703-88-5
Created by
admin on Mon Mar 31 17:55:35 GMT 2025 , Edited by admin on Mon Mar 31 17:55:35 GMT 2025
|
PRIMARY | |||
|
m6289
Created by
admin on Mon Mar 31 17:55:35 GMT 2025 , Edited by admin on Mon Mar 31 17:55:35 GMT 2025
|
PRIMARY | Merck Index | ||
|
253-162-1
Created by
admin on Mon Mar 31 17:55:35 GMT 2025 , Edited by admin on Mon Mar 31 17:55:35 GMT 2025
|
PRIMARY | |||
|
W1SO0V223F
Created by
admin on Mon Mar 31 17:55:35 GMT 2025 , Edited by admin on Mon Mar 31 17:55:35 GMT 2025
|
PRIMARY | |||
|
C601
Created by
admin on Mon Mar 31 17:55:35 GMT 2025 , Edited by admin on Mon Mar 31 17:55:35 GMT 2025
|
PRIMARY | |||
|
INOSINE PRANOBEX
Created by
admin on Mon Mar 31 17:55:35 GMT 2025 , Edited by admin on Mon Mar 31 17:55:35 GMT 2025
|
PRIMARY | |||
|
DTXSID401021342
Created by
admin on Mon Mar 31 17:55:35 GMT 2025 , Edited by admin on Mon Mar 31 17:55:35 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |